Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
Journal of Clinical Oncology2001Vol. 19(13), pp. 3210–3218
Citations Over TimeTop 1% of 2001 papers
Karen Kelly, John Crowley, Paul A. Bunn, Cary A. Presant, Patra Grevstad, Carol M. Moinpour, Scott D. Ramsey, Antoinette J. Wozniak, Geoffrey R. Weiss, Dennis F. Moore, Valerie K. Israel, Robert B. Livingston, David R. Gandara
Abstract
PC is equally efficacious as VC for the treatment of advanced non--small-cell lung cancer. PC is less toxic and better tolerated but more expensive than VC. New treatment strategies should be pursued.
Related Papers
- → Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer(2016)360 cited
- → Cell-cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy(2007)28 cited
- → Effectiveness of adjuvant carboplatin-based chemotherapy compared to cisplatin in non-small cell lung cancer(2017)13 cited
- → Weekly Carboplatin and Paclitaxel for Ovarian Cancer: The “Finer Points”(2020)4 cited
- Pharmacokinetics of paclitaxel and carboplatin in combination.(1995)